In HER2-positive non-small cell lung cancer (NSCLC) and colorectal cancer, phase 2 studies have shown promising objective response rates - tumors without anti-HER2 therapy approved until now [24,25]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.